Retrieve available abstracts of 45 articles: HTML format
Single Articles
July 2025
SANDMANN L From HCV to HEV: Repurposing a nucleoside analogue for hepatitis E therapy.
J Hepatol. 2025 Jul 31:S0168-8278(25)02322-0. doi: 10.1016/j.jhep.2025. PubMed
April 2025
HOUGHTON M A rat hepacivirus model to aid hepatitis C viral vaccine development ?
J Hepatol. 2025 Apr 16:S0168-8278(25)00243-0. doi: 10.1016/j.jhep.2025. PubMed
FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA Follow-up NIT values rather than their variation predict hepatocellular carcinoma
after HCV eradication.
J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025. PubMed
LUHMANN N, Wedemeyer H More than 10 years of IFN-free HCV treatment and viral hepatitis elimination:
Mission not completed!
J Hepatol. 2025 Apr 8:S0168-8278(25)00220-X. doi: 10.1016/j.jhep.2025. PubMed
JIN F, Gridley J, Kumari A, Saeidi A, et al Hyperfunctional T cell responses unchecked by regulatory T cells are unable to
resolve hepaciviral infection without humoral contribution.
J Hepatol. 2025;82:604-614. PubMedAbstract available
March 2025
THORSELIUS CE, Wolfisberg R, Fahnoe U, Scheel TKH, et al Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host
evolution and escape from neutralizing antibodies.
J Hepatol. 2025 Mar 15:S0168-8278(25)00163-1. doi: 10.1016/j.jhep.2025. PubMedAbstract available
SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al Recompensation of decompensated cirrhosis in hepatitis C patients after SVR:
Prognostic implications.
J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025. PubMedAbstract available
February 2025
NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al Value of non-invasive test dynamics in guiding HCC surveillance decisions after
HCV cure in patients with cirrhosis.
J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025. PubMedAbstract available
RAZAVI HA, Waked I, Qureshi H, Kondili LA, et al Number of people treated for hepatitis C virus infection in 2014-2023 and
applicable lessons for new HBV and HDV therapies.
J Hepatol. 2025 Feb 4:S0168-8278(25)00020-0. doi: 10.1016/j.jhep.2025. PubMedAbstract available
December 2024
WANG C, Tian H, Shang J Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine
research.
J Hepatol. 2024 Dec 17:S0168-8278(24)02778-8. doi: 10.1016/j.jhep.2024. PubMed
October 2024
LIU CH, Cheng PN, Fang YJ, Chen CY, et al Risk of de novo HCC in patients with MASLD following direct-acting
antiviral-induced cure of HCV infection.
J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al Agile scores in MASLD and ALD: External validation and their utility in clinical
algorithms.
J Hepatol. 2024;81:590-599. PubMedAbstract available
September 2024
LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients
after Successful Direct-Acting Antiviral Treatment.
J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024. PubMedAbstract available
August 2024
KIM SY, Shin EC Reply to: "Regulatory T cells dynamics during and after chronic hepatitis C
treatment".
J Hepatol. 2024 Aug 19:S0168-8278(24)02476-0. doi: 10.1016/j.jhep.2024. PubMed
July 2024
SOLIMAN R, Hassan A, Shiha G Regulatory T Cells dynamics during and after Chronic Hepatitis C treatment.
J Hepatol. 2024 Jul 20:S0168-8278(24)02417-6. doi: 10.1016/j.jhep.2024. PubMed
MINAMI T, Fujishiro M, Tateishi R Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4
HCV Patients following SVR and its comparison with GES score".
J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024. PubMed
KUNDU J, Le HT, Logan M, Hockman D, et al Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation
than H77C gpE2 alone.
J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024. PubMedAbstract available
June 2024
KIM SY, Koh JY, Lee DH, Kim HD, et al Epigenetic scars in regulatory T cells are retained after successful treatment of
chronic hepatitis C with direct-acting antivirals.
J Hepatol. 2024 Jun 13:S0168-8278(24)02317-1. doi: 10.1016/j.jhep.2024. PubMedAbstract available
May 2024
REIBERGER T, Lens S, Cabibbo G, Nahon P, et al EASL position paper on clinical follow-up after HCV cure.
J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024. PubMedAbstract available
SHIHA G, Mikhail N, Soliman R Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients
following SVR and its comparison with GES score.
J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024. PubMed
April 2024
KENNEDY MJ, Fernbach S, Scheel TKH Animal hepacivirus models for hepatitis C virus immune responses and pathology.
J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023. PubMed
UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al B cell characteristics define HCV reinfection outcome.
J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024. PubMedAbstract available
March 2024
SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al Post-treatment LSM rather than change during treatment predicts decompensation in
patients with cACLD after HCV cure.
J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024. PubMedAbstract available
SHEEHAN Y, Grebely J, Lloyd AR Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in
the prison - some issues".
J Hepatol. 2024;80:e107-e108. PubMed
February 2024
BIALLAS R, Zimmermann R, Dudareva S Reply to: Population-based screening works: Effect of integrating screening for
hepatitis B and C into the general health check-up in Germany.
J Hepatol. 2024 Feb 23:S0168-8278(24)00133-8. doi: 10.1016/j.jhep.2024. PubMed
LIU C, Guo C, Liu K Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and
their clinical significance.
J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024. PubMed
January 2024
HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic
Response. among People Who Inject Drugs: The HERO Study.
J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023. PubMedAbstract available
HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al Corrigendum to "Modelling the potential effectiveness of hepatitis C screening
and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023)
937-946].
J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023. PubMed
THOMPSON LA, Charlton CL Evaluation and comparison of risk-based and universal HCV screening programs.
J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023. PubMed
November 2023
COLASANTI O, Burm R, Huang HE, Riedl T, et al Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals
distinct patterns of innate immune evasion and activation" [J Hepatol (2023)
645-656].
J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023. PubMed
August 2023
DAI CY, Batsaikhan B, Huang CF 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison:
some issues.
J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023. PubMed
July 2023
MARTIN MT, Patel S, Chacra W Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case
report of an adult with short bowel syndrome.
J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023. PubMed
June 2023
MINAMI T, Sato M, Toyoda H, Yasuda S, et al Machine learning for individualized prediction of hepatocellular carcinoma
development after the eradication of hepatitis C virus with antivirals.
J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023. PubMedAbstract available
THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al Evaluation and comparison of risk-based and universal prenatal HCV screening
programs in Alberta, Canada.
J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023. PubMedAbstract available
PATEL S, Moser A, Domingo H Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023. PubMed
May 2023
DENG H, Pan Y The influence of invasive procedures on acute HBV and HCV infections.
J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023. PubMed
April 2023
KONDILI LA, Rumi MG, Craxi A Hospital HCV elimination in addition to universal precautions could reduce
incidence and infection burden in Italy.
J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023. PubMed
COLASANTI O, Burm R, Huang HE, Riedl T, et al Comparison of HAV and HCV infections in vivo and in vitro reveals distinct
patterns of innate immune evasion and activation.
J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023. PubMedAbstract available
SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance
treatment uptake in a reception prison: the PIVOT study.
J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023. PubMedAbstract available
EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for
retreatment of chronic hepatitis C.
J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023. PubMedAbstract available
CROUCHET E, Baumert TF Unraveling the role of the liver myeloid compartment during hepatitis C virus
cure.
J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023. PubMed
March 2023
TOSETTI G, Degasperi E, Farina E, Primignani M, et al Carvedilol to reduce the risk of decompensation in patients with compensated
cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral
cirrhosis?
J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023. PubMed
CUI A, Li B, Wallace MS, Gonye ALK, et al Single-cell atlas of the liver myeloid compartment before and after cure of
chronic viral hepatitis.
J Hepatol. 2023 Mar 25:S0168-8278(23)00190-3. doi: 10.1016/j.jhep.2023. PubMedAbstract available
CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al Risk of parenterally transmitted hepatitis following exposure to invasive
procedures in Italy: SEIEVA surveillance 2000-2021.
J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023. PubMedAbstract available
CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al Corrigendum to 'National trends in retreatment of HCV due to reinfection or
treatment failure in Australia' (J Hepatol [2023] 260-270).
J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023. PubMed